Related Experiment Video
Updated: Jul 10, 2026
06:34
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
Thrombopoietin: an update on therapeutic potential
1Centre for Developmental Cancer Therapeutics, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Summary
Thrombopoietin (TPO) and megakaryocyte growth and development factor (MGDF) effectively increase platelet counts and aid recovery after chemotherapy. These treatments are well-tolerated and show promise in clinical practice for managing platelet levels.
Area of Science:
- Hematology
- Molecular Biology
- Pharmacology
Background:
- Thrombopoietin (TPO) is the primary regulator of megakaryocytopoiesis.
- Understanding megakaryocyte and platelet physiology has advanced significantly since TPO's identification in 1994.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of two TPO forms: recombinant TPO (rhTPO) and megakaryocyte growth and development factor (MGDF).
- To assess the impact of TPO and MGDF on platelet recovery following myelosuppressive chemotherapy.
- To investigate the potential of TPO and MGDF in mobilizing hematopoietic progenitor cells.
Main Methods:
- Clinical trials involving administration of rhTPO and MGDF.
- Assessment of platelet counts, white cell counts, and hematocrit levels post-administration.
- Evaluation of platelet morphology and function.
- Analysis of progenitor cell mobilization in peripheral blood after chemotherapy.
Main Results:
- Both rhTPO and MGDF demonstrated equivalent biological activity in preclinical and human studies.
- TPO and MGDF administration resulted in a dose-dependent increase in platelet count without affecting white cell count or hematocrit.
- Platelets generated were morphologically and functionally normal.
- Significant enhancement of platelet recovery was observed when TPO and MGDF were administered post-myelosuppressive chemotherapy.
- TPO and MGDF mobilized progenitor cells from multiple hematopoietic lineages.
- Both TPO forms were well-tolerated with minimal acute toxicities.
Conclusions:
- TPO and MGDF are potent agents for increasing platelet counts and accelerating platelet recovery after chemotherapy.
- The scheduling of TPO/MGDF administration relative to chemotherapy may be crucial for optimizing outcomes.
- These agents have the potential to mobilize hematopoietic progenitor cells, possibly augmenting the effects of other growth factors.
- Further clinical studies are ongoing to define the exact role of TPO in clinical practice.
Related Concept Videos
01:28Role of Hematopoietic Growth Factors
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include: